Dianthus Q2 net loss $50.2M; CIDP trial 75% response; cash $1.2B

Dianthus Therapeutics, Inc. /DE/

Net loss $50.2M ($0.90/share) vs $31.6M ($0.88) in Q2 2025; R&D $48.7M, G&A $13.6M.
Cash $1.2B as of June 30, 2026, providing runway into 2030.
Phase 3 CAPTIVATE (CIDP) interim: 75% response rate in first 40 patients; Part B guidance by YE'26.
Phase 3 EMERGE (gMG) initiated; top-line results expected 2H'28.
Phase 2 MoMeNtum (MMN) enrollment completed (46 patients); top-line Dec '26.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.